[{"id":"8c7009ed-e696-4413-8754-ce881c82a637","acronym":"","url":"https://clinicaltrials.gov/study/NCT05043298","created_at":"2021-09-14T16:53:19.304Z","updated_at":"2024-07-02T16:36:03.594Z","phase":"Phase 1a/1b","brief_title":"A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05043298","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" HER-2 • CLDN18","pipe":" | ","alterations":" HER-2 negative • CLDN18.2 expression","tags":["HER-2 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • IBI360"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 10/27/2021","start_date":" 10/27/2021","primary_txt":" Primary completion: 03/25/2024","primary_completion_date":" 03/25/2024","study_txt":" Completion: 06/18/2024","study_completion_date":" 06/18/2024","last_update_posted":"2022-09-22"}]